Eric Cantor Joins Pharma Lobby Group as New CEO
Former Rep. Eric Cantor named president of PhRMA, the leading drug industry lobbying group.
2 min read
Former Republican Virginia Rep. Eric Cantor has been named the next president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), the organization announced Tuesday. Cantor will assume his new role effective November 9, marking a significant shift in his career following his departure from Congress.
Political and Business Background
Cantor represented Virginia’s 7th congressional district from 2000 to 2014, serving as House majority leader from 2011 to 2014 before losing his re-election bid in a major upset. Since leaving Congress, he has worked as vice chairman and managing director at global investment bank Moelis & Company.
PhRMA Leadership Statement
PhRMA Board of Directors Chair Rob Davis praised Cantor’s leadership qualities, stating, “Eric is well respected among policy leaders in Washington and around the world, with a long track record of working effectively across the political spectrum to achieve important outcomes that have a lasting impact.” Davis added, “Eric’s unique combination of global business acumen coupled with policy and political experience at the highest levels of government makes him an ideal person to lead PhRMA during this critical next chapter.”
Industry Contributions and Vision
Cantor highlighted his contributions to the biopharmaceutical industry, including his role in laying the groundwork for the 21st Century Cures Act, a landmark bipartisan bill that increased NIH funding and included FDA reforms to speed medicine approvals. He emphasized the importance of advancing innovation and expanding patient access to medicines.
PhRMA Leadership Transition
The announcement comes after PhRMA announced that its current president and CEO, Stephen Ubl, plans to step down at the end of 2026. Cantor’s appointment is seen as a strategic move to position PhRMA for continued growth and influence in the pharmaceutical sector.
Public Response and Comments
PhRMA provided a press release as the primary source of information, and Cantor did not immediately respond to requests for comment. His new role is expected to shape the future of the pharmaceutical industry’s engagement with policymakers and regulatory bodies.
Source: Daily Caller
